Average cost of drugs for extensively drug-resistant tuberculosis in Senegal
Senegal: Average cost of drugs for extensively drug-resistant tuberculosis was 3,428 constant 2022 US$ in 2024. ◆ Volatile
Latest (2024)
3,428 constant 2022 US$
Change on year
unchanged
World rank
20th
of 56 countries
All-time high
5,308 constant 2022 US$
in 2018
All-time low
10 constant 2022 US$
in 2022
Years of data
5
2018–2024
Average cost of drugs for extensively drug-resistant tuberculosis in Senegal, 2018–2024
Source: WHO (2025) – with minor processing by Our World in Data. Measured in constant 2022 US$.
Analysis
In 2024, average cost of drugs for extensively drug-resistant tuberculosis in Senegal stood at 3,428 constant 2022 US$.
That represents a change of down 35.4% over ten years.
That places Senegal 20th out of 56 countries with data for 2024, putting it in the middle of the range.
Average cost of drugs for extensively drug-resistant tuberculosis in Senegal, year by year
| Year | constant 2022 US$ | Change |
|---|---|---|
| 2018 | 5,308 constant 2022 US$ | — |
| 2020 | 4,695 constant 2022 US$ | -11.5% |
| 2022 | 10 constant 2022 US$ | -99.8% |
| 2023 | 3,428 constant 2022 US$ | +34180.0% |
| 2024 | 3,428 constant 2022 US$ | +0.0% |
Senegal compared with similar countries
- Senegal's 3,428 constant 2022 US$ is above the median for lower middle income countries, which is 1,525 constant 2022 US$, 2.2× the median. (24 countries reporting)
- Senegal's 3,428 constant 2022 US$ is above the median for Sub-Saharan Africa, which is 1,500 constant 2022 US$, 2.3× the median. (20 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 5,308 constant 2022 US$ | 5,308 constant 2022 US$ | 5,308 constant 2022 US$ | 1 |
| 2020s | 2,890 constant 2022 US$ | 10 constant 2022 US$ | 4,695 constant 2022 US$ | 4 |
Countries ranked near Senegal
More reference data data for Senegal
- Emission Totals - Indirect emissions (N2O) - Manure applied to Soils 0.2247 (2050)
- Emission Totals - Indirect emissions (N2O) - Manure left on Pasture 3.89 (2050)
- Emission Totals - Indirect emissions (N2O) - IPCC Agriculture 4.55 (2050)
- Emission Totals - Indirect emissions (N2O) - Crop Residues 0.1649 (2050)
- Emission Totals - Indirect emissions (N2O) - Agricultural Soils 4.55 (2050)
- Emission Totals - Emissions (N2O) - Manure applied to Soils 0.7534 (2050)
- Emission Totals - Emissions (N2O) - Manure Management 0.5106 (2050)
- Emission Totals - Emissions (N2O) - Manure left on Pasture 17.48 (2050)
- Emission Totals - Emissions (N2O) - IPCC Agriculture 20.77 (2050)
- Emission Totals - Emissions (N2O) - Crop Residues 0.8979 (2050)
Frequently asked questions
- What is average cost of drugs for extensively drug-resistant tuberculosis in Senegal?
- Average cost of drugs for extensively drug-resistant tuberculosis in Senegal was 3,428 constant 2022 US$ in 2024, according to WHO (2025) – with minor processing by Our World in Data.
- What is the highest average cost of drugs for extensively drug-resistant tuberculosis recorded in Senegal?
- The highest recorded value was 5,308 constant 2022 US$ in 2018.
- What is the lowest average cost of drugs for extensively drug-resistant tuberculosis recorded in Senegal?
- The lowest recorded value was 10 constant 2022 US$ in 2022.
- How does Senegal rank for average cost of drugs for extensively drug-resistant tuberculosis?
- Senegal ranks 20th out of 56 countries with data for 2024.
- Is average cost of drugs for extensively drug-resistant tuberculosis rising or falling in Senegal?
- Over the last ten years it is down 35.4%. The long-run trend across the full record is volatile.
- Where does this Senegal data come from?
- The figures come from WHO (2025) – with minor processing by Our World in Data, published as part of Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 5 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.